Elancheran Ramakrishnan - Recent discoveries and developments of androgen receptor based therapy for prostate cancer

Document created by Elancheran Ramakrishnan on May 22, 2016
Version 1Show Document
  • View in full screen mode

  Publication Details (including relevant citation   information):

Med. Chem. Commun., 2015,6, 746-768

    DOI: 10.1039/C4MD00416G


    The main focus of this review is to discuss the discoveries and   developments of various therapies for prostate cancer. The AR has   played an important role in prostate cancer growth and functions.   This review discusses several groups of drugs that have sparingly   good anti-cancer activities, as well as a similar structure and   behaviour. A recent new-generation AR antagonist, Enzalutamide   (MDV3100), has been approved for the treatment of   advanced/metastatic prostate cancer. Nonsteroidal antiandrogens   represent an important class of molecules acting as either   antagonists or agonists. Recently, many therapeutic agents for   prostate cancer that target the androgen receptor and reduce   prostate tumour growth have been approved. The strong response to   this new use of Enzalutamide provides a viable, less toxic   alternative to chemotherapy. The current status of prostate   cancer drugs are discussed here, but it is evident that   considerably more work is needed for improvements in respect to   efficacy, reduction of the side effects and treatment   strategies.

  Address (URL): http://pubs.rsc.org/en/content/articlelanding/2015/md/c4md00416g#!divAbstract